Spartalizumab  (Synonyms: PDR001)

Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a K_d of 0.83 nM for human PD-1 and a K_d of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs)^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Spartalizumab binds to human and cynomolgus monkey PD-1 with mean K_d values of 0.83 nM and 0.93 nM, respectively, and does not bind to mouse PD-1^[1].
Spartalizumab (incubated at 4°C for 4 h) inhibits the binding of PD-1 to PD-L1 and PD-L2 in PD-1-expressing murine 300.19 cells, with IC₅₀ values of 0.9 nM and 1.3 nM, respectively^[1].
Spartalizumab induces a concentration-dependent increase in IFNγ release in mixed lymphocyte reaction assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.14 kDa

1935694-88-4

Liquid

Colorless to light yellow

[Spartalizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized PD-1 Protein, Human can bind Spartalizumab. The EC₅₀ for this effect is 14.84 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) with Spartalizumab (HY-P9972, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Naing A, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020 Mar;8(1):e000530.  [Content Brief]

  [2]. Capdevila J, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020;38(23):2620-2627.  [Content Brief]